Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Invasive Bladder Cancer × durvalumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 76 Lung Neoplasms 36 Carcinoma, Hepatocellular 35 Small Cell Lung Carcinoma 25 Cholangiocarcinoma 18 Urinary Bladder Neoplasms 17 Breast Neoplasms 17 Neoplasms 14 Colorectal Neoplasms 13 Triple Negative Breast Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 12 Biliary Tract Neoplasms 10 Liver Neoplasms 9 Pancreatic Neoplasms 8 Ovarian Neoplasms 8 Esophageal Neoplasms 8 Stomach Neoplasms 7 Recurrence 7 Neoplasm Metastasis 7 Head and Neck Neoplasms 7 Prostatic Neoplasms 6 Melanoma 6 Carcinoma, Transitional Cell 6 Carcinoma, Renal Cell 6 Bile Duct Neoplasms 6 Neoplasms by Site 5 Mesothelioma, Malignant 5 Endometrial Neoplasms 5 Adenocarcinoma 5 Uterine Cervical Neoplasms 4

Interventions

tremelimumab 1 durvalumab 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03702179 2024-12-05

IMMUNOPRESERVE

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

32 enrolled 19 charts

Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡